Forge Biologics: Valuation, Funding & Investors
Forge Biologics is a contract development and manufacturing organization (CDMO) focused on enabling gene and cell therapy programs through GMP viral vector manufacturing and associated development services. The company provides end-to-end capabilities including process and analytical development, AAV and lentiviral production, fill/finish, and regulatory support to biopharmaceutical clients advancing clinical and commercial gene therapies.
Leadership & Board
- Current Number of Employees
- 438
- Current LinkedIn Followers
- 34,633
Latest Estimated Valuation
- Total Amount Raised
- $90M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $90M
- Latest Funding Round
- Series C
Company Momentum
PositiveForge Biologics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Forge Biologics had 438 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Forge Biologics had 34,633 followers as of November 16, 2026. The number of followers increased by 57 (0.16%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 12, 2022 | Series C | $90.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Drive Capital | Series C |
| Aisling Capital | Series C |
Similar Companies
A snapshot of private companies similar to Forge Biologics, helping you discover and navigate related company profiles.
Related News and Analysis








